Imakrebin (Imatinib)

Imatinib, the active ingredient in Imakrebin, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is used to treat certain blood cancers and gastrointestinal stromal tumors in adult patients.

GNH USA supplies Imakrebin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imakrebin is a targeted therapy that interferes with abnormal tyrosine‑kinase signaling in specific malignancies.

- Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL kinase activity. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): helps achieve remission through the same molecular blockade. - Gastrointestinal stromal tumor (GIST): reduces tumor size and progression by targeting c‑KIT and PDGFR kinases.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may be watery.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells increasing infection risk. - Cardiac failure: signs of reduced heart function such as shortness of breath.

Patients should be monitored closely for safety concerns before and during therapy.

- Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function assessment: check hepatic enzymes at baseline and periodically. - Cardiac evaluation: assess cardiac status in patients with pre‑existing heart disease. - Pregnancy considerations: avoid use during pregnancy unless benefits outweigh risks; safety data are limited. - Dose adjustment in hepatic impairment: consider reduced dosing in moderate to severe liver dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Imakrebin may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy by reducing drug exposure. - Antacids containing aluminum or magnesium: can decrease oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal bleeding. - Live vaccines: immunosuppression may reduce vaccine efficacy; avoid if possible.